ArticleAnnals of surgical oncology2026
Impact of Ideal Outcome on Survival and Treatment Continuity After Pancreatoduodenectomy for Resectable Pancreatic Head Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdeal outcome (IO) after pancreatoduodenectomy (PD) is a harmonized composite perioperative quality measure, but its association with long-term oncological outcomes remains unknown.
methodsWe retrospectively analyzed 138 consecutive patients undergoing PD for resectable pancreatic head cancer from 2019 to 2024. IO was defined as the absence of in-hospital mortality, severe complications, clinically relevant postoperative pancreatic fistula, reoperation, prolonged hospital stay, and unplanned readmission. Overall survival (OS), recurrence-free survival, and post-recurrence survival were compared by IO status.
resultsIO was achieved in 80 patients (58%). The 5 years OS was 74.7% in the IO achievement group versus 46.0% in the non-achievement group (p = 0.011); 3 years recurrence-free survival was 59.7% versus 49.7% (p = 0.151). On multivariable analysis, IO achievement was independently associated with favorable OS (p = 0.036). IO achievement was also associated with higher adjuvant chemotherapy initiation (86.1% vs. 67.2%; p = 0.015), earlier initiation (postoperative day 44 vs. 56; p < 0.001), and superior postoperative nutritional and inflammatory profiles. At recurrence, IO achievement was associated with longer post-recurrence survival (median 15 vs. 6 months; p = 0.009).
conclusionsIO achievement might serve as a composite marker reflecting physiological reserve after PD for resectable pancreatic head cancer.
Indexed as
Identifiers
42799829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.